Cargando…

Author Correction: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma

Detalles Bibliográficos
Autores principales:	Adamia, Sophia, Bhatt, Shruti, Wen, Kenneth, Chyra, Zuzana, Fell, Geoffrey G., Tai, Yu-Tzu, Pioso, Marissa S., Abiatari, Ivane, Letai, Anthony, Dorfman, David M., Hideshima, Teru, Anderson, Kenneth C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162917/ https://www.ncbi.nlm.nih.gov/pubmed/35513704 http://dx.doi.org/10.1038/s41375-022-01588-z

Ejemplares similares

Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma
por: Adamia, Sophia, et al.
Publicado: (2022)

Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics
por: Ogiya, Daisuke, et al.
Publicado: (2023)

Signaling Pathway Mediating Myeloma Cell Growth and Survival
por: Hideshima, Teru, et al.
Publicado: (2021)

PRMT5 inhibitors on the (myeloma) road
por: Gulla, Annamaria, et al.
Publicado: (2018)

The biological significance of histone modifiers in multiple myeloma: clinical applications
por: Ohguchi, Hiroto, et al.
Publicado: (2018)

Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications
por: Ohguchi, Hiroto, et al.
Publicado: (2021)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
por: Hideshima, Teru, et al.
Publicado: (2008)

Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma
por: Jakubikova, Jana, et al.
Publicado: (2023)

HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications
por: Harada, Takeshi, et al.
Publicado: (2017)

KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival
por: Ohguchi, Hiroto, et al.
Publicado: (2017)

BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
por: Kurata, Keiji, et al.
Publicado: (2023)

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy
por: Richardson, Paul, et al.
Publicado: (2010)

The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010)

Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma
por: Bae, Jooeun, et al.
Publicado: (2021)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma
por: Yao, Yao, et al.
Publicado: (2023)

A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications
por: Jakubikova, Jana, et al.
Publicado: (2016)

Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells
por: Suzuki, Rikio, et al.
Publicado: (2015)

ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment
por: Liu, Jiye, et al.
Publicado: (2021)

Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
por: Bhatt, Parva, et al.
Publicado: (2023)

IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells
por: HIDESHIMA, HIROMASA, et al.
Publicado: (2014)

Protein Arginine Methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in Multiple Myeloma
por: Gullà, Annamaria, et al.
Publicado: (2017)

Retraction: Fatty acid synthase is a novel therapeutic target in multiple myeloma
por: Okawa, Yutaka, et al.
Publicado: (2008)

A Novel Role for CCL3 (MIP-1α) in Myeloma-induced Bone Disease via Osteocalcin Downregulation and Inhibition of Osteoblast Function
por: Vallet, Sonia, et al.
Publicado: (2011)

Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
por: Joseph, Nisha S, et al.
Publicado: (2021)

Gallbladder agenesis: A case report and review of the literature
por: Pipia, Irakli, et al.
Publicado: (2018)

The State of Public Health Education and Science During and After the Fall of the Soviet Union: Achievements, Remaining Challenges, and Future Priorities
por: Gotsadze, George, et al.
Publicado: (2022)

Randomized, placebo‐controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib
por: Richardson, Paul G., et al.
Publicado: (2020)

The KDM3A–KLF2–IRF4 axis maintains myeloma cell survival
por: Ohguchi, Hiroto, et al.
Publicado: (2016)

Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling
por: Ho, Matthew, et al.
Publicado: (2019)

Relapsing polychondritis – analysis of symptoms and criteria
por: Maciążek-Chyra, Beata, et al.
Publicado: (2019)

Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways
por: Hideshima, Teru, et al.
Publicado: (2020)

Antibody-Based Therapies in Multiple Myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2011)

Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)

Small Molecule Multi-Targeted Kinase Inhibitor RGB-286638 Triggers P53-Dependent and -Independent Anti-Multiple Myeloma Activity through Inhibition of Transcriptional CDKs
por: Cirstea, Diana, et al.
Publicado: (2013)

Relapsing Cutaneous Multiple Myeloma Responding to Immunochemotherapy: A Rare Case Report
por: Mohamed, Mujtaba, et al.
Publicado: (2019)

Pericardial relapse of multiple myeloma
por: Jamison, Lee S, et al.
Publicado: (2020)

Moesin-dependent cytoskeleton remodelling is associated with an anaplastic phenotype of pancreatic cancer
por: Abiatari, Ivane, et al.
Publicado: (2010)

An Erk/Cdk5 axis controls the diabetogenic actions of PPARγ
por: Banks, Alexander S., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_8culgl243059gp2358c9u5e2fv